ASHP Pushes to End White Bagging: What It Means for Specialty Drug Distribution

The American Society of Health-System Pharmacists issued a formal position statement in January 2025 calling for the elimination of white bagging practices in specialty pharmacy. This advocacy directly challenges the distribution model used by payers to reduce drug costs, and it has operational implications for 3PLs and specialty drug distributors that service both health systems and third-party payers.

Regulatory and Practice Context

White bagging refers to the practice where a health insurer or pharmacy benefit manager directs a patient to obtain a specialty drug from a mail-order or specialty pharmacy, which then ships the medication directly to the infusion center or physician's office for administration. The practice emerged as a cost-containment strategy, allowing payers to negotiate drug pricing directly rather than reimbursing providers under the traditional buy-and-bill model.

Brown bagging, a related practice, involves the patient physically transporting the medication from the pharmacy to the administration site. Both models differ from buy-and-bill, where the provider purchases the drug, administers it, and bills the insurer for both the product and the service.

White bagging operates in a regulatory gray area. The Drug Supply Chain Security Act (21 U.S.C. § 360eee) requires trading partners to exchange transaction information, transaction history, and transaction statements when transferring ownership of prescription drugs. However, DSCSA does not explicitly prohibit or regulate white bagging as a distinct distribution model. State pharmacy boards have varying positions: some states require the dispensing pharmacy to be licensed where the patient receives care; others do not specifically address the practice.

ASHP's position centers on patient safety concerns, not federal statute violations. The organization argues that white bagging introduces risks including improper storage during shipment, delays in treatment when shipments arrive late or damaged, lack of clinical oversight at the dispensing pharmacy, and waste when drugs arrive but cannot be used due to changes in the patient's condition or insurance status.

Operational Implications for Specialty Drug Logistics

For 3PLs and wholesale drug distributors operating in the specialty pharmacy space, ASHP's advocacy creates uncertainty in a growing service line. White bagging logistics require cold chain integrity across a fragmented distribution path: from manufacturer to specialty pharmacy, specialty pharmacy to cold chain courier, courier to infusion center. Each handoff is a compliance and quality control checkpoint.

If ASHP's position gains traction with state legislatures or payers voluntarily reduce white bagging programs, distributors can expect two shifts. First, increased volume in traditional buy-and-bill distribution — health systems would order more specialty drugs directly from wholesalers rather than receiving them from mail-order pharmacies. This benefits traditional wholesale channels but may reduce revenue for distributors embedded in payer-directed white bagging networks.

Second, heightened scrutiny of temperature control and chain of custody documentation. Even if white bagging continues, providers receiving white-bagged products will likely impose stricter receiving standards to mitigate the liability ASHP highlighted. Distributors supporting these shipments will need robust data logging for temperature excursions and serialization verification at each transfer point.

State pharmacy boards may also begin explicitly regulating white bagging if ASHP's advocacy elevates the issue. Ohio and Texas, the states with the highest number of licensed wholesale drug distributors in ColdChainCheck's directory, have not issued formal guidance on white bagging logistics requirements. That regulatory silence may not last if patient safety incidents linked to white bagging accumulate.

340B covered entities face additional complexity. White bagging can complicate 340B drug replenishment when the specialty pharmacy dispensing the drug is not the covered entity's contract pharmacy. If white bagging is restricted, 340B hospitals may need to restructure their specialty pharmacy relationships to maintain program eligibility while sourcing high-cost drugs.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions, 63 of which hold NABP accreditation — a credential increasingly relevant as white bagging scrutiny intensifies. The average compliance score across all entities is 51/100, placing most distributors in the "Fair" tier. Only 28 entities score in the "Excellent" range (75-100 points), meaning fewer than 3% of tracked entities have comprehensive, verified compliance signals across state licensure, federal registration, accreditation, and enforcement history.

For specialty drug logistics specifically, this distribution matters. Entities supporting white bagging workflows operate in a higher-risk environment than traditional wholesale channels. A Fair-tier compliance score reflects incomplete public data verification — not necessarily non-compliance, but an absence of multiple verified checkpoints. Health systems and specialty pharmacies evaluating white bagging partners should prioritize distributors with NABP accreditation and FDA registration at minimum. Of the 1,234 entities with verified FDA registration in ColdChainCheck's directory, only 63 also hold NABP accreditation, indicating a narrow pool of fully credentialed specialty logistics providers.

The 73 entities with FDA recalls on record represent 5.7% of the directory. Not all recalls involve temperature-controlled products, but the presence of any enforcement action signals elevated due diligence requirements. If ASHP's position prompts increased regulatory attention to white bagging cold chain failures, entities with existing recall histories may face stricter scrutiny from both state boards and provider partners.

Practical Steps for QA and Compliance Teams

• Verify specialty pharmacy distributor credentials now: Use the ColdChainCheck directory to cross-reference state licenses, FDA registration, and NABP accreditation for any 3PL or distributor in your white bagging supply chain. Filter by state and sort by compliance score to identify gaps before regulatory pressure increases.

• Document temperature control capabilities: If your organization receives white-bagged specialty drugs, request temperature monitoring logs and serialization data from the dispensing pharmacy and courier. Entities scoring below 50 in the directory may lack public verification of cold chain infrastructure — escalate due diligence for those partners.

• Monitor state pharmacy board actions: Ohio and Texas combined represent the highest concentration of licensed distributors in the directory. If either state issues white bagging guidance, expect other jurisdictions to follow. ColdChainCheck's 3PL licensing requirements guide tracks state-level regulatory developments affecting wholesale drug distribution.

• Reassess buy-and-bill sourcing capacity: If your health system relies heavily on white bagging for specialty drugs, map alternative wholesaler relationships in case payer policies shift. Entities with Excellent or Good compliance scores (309 total in the directory) represent the most defensible sourcing options for direct specialty drug procurement.

Disclaimer: This article provides informational analysis of regulatory developments affecting pharmaceutical wholesale distribution. It is not legal advice. Entities should consult qualified legal counsel and verify compliance requirements with applicable state pharmacy boards and federal agencies.